SimBioSys, Inc.

SimBioSys, Inc. is a company focused on advanced visualization and diagnostic technology to enhance precision medicine in oncology. Founded in 2018 and headquartered in Chicago, US, SimBioSys, Inc. develops innovative tools for cancer surgeons.

The company has pivoted to emphasize cloud-based solutions and has successfully raised USD 15. 000 mn in Series A funding on October 26, 2021, to further its initiatives. The founding team includes John C and Joseph Peterson, with Tushar Pandey serving as CEO. SimBioSys specializes in advanced visualization and diagnostic technology aimed at revolutionizing precision medicine within oncology.

The company's flagship product, TumorSight Viz, is a cloud-based tool that has received U. S. FDA clearance and is specifically designed to assist breast cancer surgeons in the preoperative planning of procedures such as breast conservation surgery. TumorSight Viz transforms traditional 2D DCE-MRI studies into interactive 3D models, facilitating crucial calculations such as tumor volume and proximity to anatomical features.

This technology addresses the complexity of tumor heterogeneity, enabling clinicians to visualize tumors in their entirety—beyond standard biopsies and pathology slides. The company serves a range of clients, including top cancer centers and healthcare professionals across the United States, aiming to improve patient outcomes via individualization of treatment strategies. Additionally, SimBioSys offers complementary solutions such as TumorSight Risk and PhenoScope, which further enhance their diagnostic capabilities and research applications in various oncology settings. SimBioSys engages in B2B transactions primarily with healthcare institutions and professionals, providing subscription-based access to their suite of diagnostic tools.

Revenue is generated through partnerships with leading cancer centers and healthcare systems, allowing these organizations to integrate TumorSight products into their clinical workflows. The pricing structure includes different tiers based on the specific tool utilized, with flagship offerings like TumorSight Viz forming the backbone of their commercial strategy. These transactions are facilitated through direct contracts with hospitals and clinics, establishing a reliable revenue stream as healthcare providers seek innovative solutions to improve cancer treatment planning and patient management. As the company expands its product offerings, it aims to solidify its presence in the oncology market, supported by a growing base of users in the United States.

In October 2021, SimBioSys, Inc. raised USD 15. 000 mn in Series A funding co-led by new investors Genoa Ventures and Northpond Ventures, with participation from other investors AV8 Ventures, Heritage Medical Systems, and Mayo Clinic Ventures. The funding will be utilized to accelerate the development and commercialization of its TumorScope software platform.

The company plans to design and launch upcoming products targeting enhanced diagnostic capabilities, with specific attention to their integration into new market segments. SimBioSys is also focusing on expanding its presence beyond the U. S. healthcare sector, with strategies aimed at entering international markets by 2024.